374 related articles for article (PubMed ID: 35081970)
1. Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer.
Raj S; Kesari KK; Kumar A; Rathi B; Sharma A; Gupta PK; Jha SK; Jha NK; Slama P; Roychoudhury S; Kumar D
Mol Cancer; 2022 Jan; 21(1):31. PubMed ID: 35081970
[TBL] [Abstract][Full Text] [Related]
2. Roles of the HGF/Met signaling in head and neck squamous cell carcinoma: Focus on tumor immunity (Review).
Liu D; Zhong M; Zhan D; Zhang Y; Liu S
Oncol Rep; 2020 Dec; 44(6):2337-2344. PubMed ID: 33125120
[TBL] [Abstract][Full Text] [Related]
3. HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
Hartmann S; Bhola NE; Grandis JR
Clin Cancer Res; 2016 Aug; 22(16):4005-13. PubMed ID: 27370607
[TBL] [Abstract][Full Text] [Related]
4. Activated HGF-c-Met Axis in Head and Neck Cancer.
Arnold L; Enders J; Thomas SM
Cancers (Basel); 2017 Dec; 9(12):. PubMed ID: 29231907
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
[TBL] [Abstract][Full Text] [Related]
6. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Knowles LM; Stabile LP; Egloff AM; Rothstein ME; Thomas SM; Gubish CT; Lerner EC; Seethala RR; Suzuki S; Quesnelle KM; Morgan S; Ferris RL; Grandis JR; Siegfried JM
Clin Cancer Res; 2009 Jun; 15(11):3740-50. PubMed ID: 19470725
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.
Dong G; Chen Z; Li ZY; Yeh NT; Bancroft CC; Van Waes C
Cancer Res; 2001 Aug; 61(15):5911-8. PubMed ID: 11479233
[TBL] [Abstract][Full Text] [Related]
8. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
9. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell.
Lim YC; Kang HJ; Moon JH
Oral Oncol; 2014 Jul; 50(7):633-9. PubMed ID: 24835851
[TBL] [Abstract][Full Text] [Related]
10. c-Met Signaling as a Therapeutic Target in Head and Neck Cancer.
Centuori SM; Bauman JE
Cancer J; 2022 Sep-Oct 01; 28(5):346-353. PubMed ID: 36165722
[TBL] [Abstract][Full Text] [Related]
11. The Influence of Met Receptor Level on HGF-Induced Glycolytic Reprogramming in Head and Neck Squamous Cell Carcinoma.
Boschert V; Klenk N; Abt A; Janaki Raman S; Fischer M; Brands RC; Seher A; Linz C; Müller-Richter UDA; Bischler T; Hartmann S
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940827
[TBL] [Abstract][Full Text] [Related]
12. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma.
De Herdt MJ; Baatenburg de Jong RJ
Front Biosci; 2008 Jan; 13():2516-26. PubMed ID: 17981731
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment.
Rothenberger NJ; Stabile LP
Cancers (Basel); 2017 Apr; 9(4):. PubMed ID: 28441771
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic target for head and neck squamous cell carcinoma: HGF-MET signaling pathway.
Lau PC; Chan AT
Anticancer Drugs; 2011 Aug; 22(7):665-73. PubMed ID: 21709616
[TBL] [Abstract][Full Text] [Related]
15. Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas.
Galeazzi E; Olivero M; Gervasio FC; De Stefani A; Valente G; Comoglio PM; Di Renzo MF; Cortesina G
Eur Arch Otorhinolaryngol; 1997; 254 Suppl 1():S138-43. PubMed ID: 9065649
[TBL] [Abstract][Full Text] [Related]
16. Receptor-type Protein tyrosine phosphatase β regulates met phosphorylation and function in head and neck squamous cell carcinoma.
Xu Y; Zhou J; Carey TE; McHugh JB; Voorhees JJ; Fisher GJ
Neoplasia; 2012 Nov; 14(11):1015-22. PubMed ID: 23226095
[TBL] [Abstract][Full Text] [Related]
17. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
19. Understanding c-MET signalling in squamous cell carcinoma of the head & neck.
Szturz P; Raymond E; Abitbol C; Albert S; de Gramont A; Faivre S
Crit Rev Oncol Hematol; 2017 Mar; 111():39-51. PubMed ID: 28259294
[TBL] [Abstract][Full Text] [Related]
20. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.
Stabile LP; He G; Lui VW; Thomas S; Henry C; Gubish CT; Joyce S; Quesnelle KM; Siegfried JM; Grandis JR
Clin Cancer Res; 2013 Jan; 19(2):380-92. PubMed ID: 23213056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
